Bromocriptine in type 2 diabetes mellitus

  title={Bromocriptine in type 2 diabetes mellitus},
  author={Channabasappa Shivaprasad and Sanjay Kalra},
  booktitle={Indian journal of endocrinology and metabolism},
Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased plasma glucose, free fatty acids, and triglycerides in… CONTINUE READING